https://scholars.lib.ntu.edu.tw/handle/123456789/462186
Title: | Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study | Authors: | SHU-CHEN WEI PO-NIEN TSAO Wang Y.-T. BEEN-REN LIN Wu D.-C. Tsai W.-S. Chen J.-S. Wong J.-M. |
Issue Date: | 2019 | Publisher: | Blackwell Publishing Ltd | Journal Volume: | 8 | Journal Issue: | 7 | Start page/Pages: | 3583-3591 | Source: | Cancer Medicine | Abstract: | Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Screening for CRC using the fecal occult blood test (FOBT) is feasible and useful for decreasing disease-related mortality; however, its sensitivity and compliance are unsatisfactory. Methods: This study examined the efficacy of using serum placenta growth factor (PlGF) for a novel CRC screening strategy. To investigate a potential novel screening tool for CRC, we compared the sensitivity, specificity, positive predictive value, and negative predictive value of the FOBT, serum PlGF, and their combination through an examination of two independent cohorts and validation using the second cohort. All the patients and control group received the colonoscopy and FOBT, the colonoscopy was used as the gold standard for the result. Results: Serum PlGF levels were significantly increased in CRC patients (16.8?±?11.4?pg/mL) compared with controls (12.0?±?11.2?pg/mL). The predictive model that used the serum PlGF level alone was as effective as the FOBT (AUC: 0.60 vs 0.68, P?=?0.891), and it had significantly higher sensitivity than the FOBT (0.81 vs 0.39). In addition, we found serum PlGF level has a good value for predicting CRC patients in those FOBT negative populations. Finally, combining serum PlGF level and the FOBT improved the predictive power and demonstrated satisfactory sensitivity (0.71) and specificity (0.71). This result was confirmed and validated in the second independent cohort. Furthermore, no matter the stages (early/advanced) and the location (distal/proximal) of CRC, the efficacy of serum PlGF and the combined model remained quite stable. Conclusion: Serum PlGF level is a potential alternative screening tool for CRC, especially for those who are reluctant to stool-based screening methods and who were tested as negative FOBT. In addition, combining serum PlGF level and the FOBT could increase the power of CRC screening. ? 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068427079&doi=10.1002%2fcam4.2216&partnerID=40&md5=d693e55c9b00a52600bd423d17194e52 https://scholars.lib.ntu.edu.tw/handle/123456789/462186 |
ISSN: | 2045-7634 | DOI: | 10.1002/cam4.2216 | SDG/Keyword: | placental growth factor; biological marker; PGF protein, human; placental growth factor; adult; Article; cancer patient; cancer screening; cohort analysis; colonoscopy; colorectal cancer; controlled study; diagnostic test accuracy study; false negative result; false positive result; female; gold standard; human; major clinical study; male; multicenter study; occult blood test; predictive value; priority journal; protein blood level; sensitivity and specificity; validation study; aged; area under the curve; blood; cancer staging; clinical trial; colorectal tumor; early cancer diagnosis; mass screening; middle aged; procedures; prognosis; reproducibility; Adult; Aged; Area Under Curve; Biomarkers; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Male; Mass Screening; Middle Aged; Neoplasm Staging; Placenta Growth Factor; Prognosis; Reproducibility of Results; Sensitivity and Specificity |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.